✦ LIBER ✦

TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial

✍ Scribed by Xu, Bo; Gao, Run-Lin; Lansky, Alexandra; Yang, Yuejin; Changsheng, Ma; Han, Yaling; Chen, Shao Liang; Li, Hui; Zhang, Ruiyan; Fu, Guosheng; Yuan, Zuyi; Huo, Yong; Li, Wei; Zhao, Yelin; Leon, Martin

Book ID: 122273691
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 100 KB
Volume: 62
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2013.08.748

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TCT-590 Three-Year Clinical Follow-Up of

TCT-590 Three-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Single De Novo Native Coronary Lesions: The TARGET I Trial

✍ Xu, Bo; Zhao, Yelin; Yang, Yuejin; Changsheng, Ma; Han, Yaling; Chen, Shao Liang 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 74 KB

TCT-242: First Report of A Novel Ablumin

TCT-242: First Report of A Novel Abluminal Groove Filled Biodegradable Polymer Rapamycin-Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man FIREHAWK Trial

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 213 KB

TCT-181 Safety and Efficacy of a Novel A

TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials

✍ Gao, Run-Lin; Xu, Bo; Lansky, Alexandra; Yang, Yuejin; Zhang, Ruiyan; Changsheng 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Randomized Comparison of Everolimus-Elut

Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial

✍ Stone, G. W.; Midei, M.; Newman, W.; Sanz, M.; Hermiller, J. B.; Williams, J.; F 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 436 KB

Four-year clinical follow-up of the XIEN

Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial

✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat

TCT-244: A Clinical Evaluation of the Pr

TCT-244: A Clinical Evaluation of the ProNOVA XR Polymer Free Sirolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Coronary Artery Lesions (EURONOVA Study)

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 83 KB